These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 14706214)

  • 41. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
    Bi Z; Cao Y; Gui M; Lin J; Zhang Q; Li Y; Ji S; Bu B
    Neurol Sci; 2023 Apr; 44(4):1383-1391. PubMed ID: 36469201
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects.
    Sommer N; Melms A; Weller M; Dichgans J
    Doc Ophthalmol; 1993; 84(4):309-33. PubMed ID: 8156854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dermatomyositis and myastenia gravis: An uncommon association with therapeutic implications.
    Sangüesa Gómez C; Flores Robles BJ; Méndez Perles C; Barbadillo C; Godoy H; Andréu JL
    Reumatol Clin; 2015; 11(4):244-6. PubMed ID: 25498320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myasthenia gravis: an unusual cause of diplopia in polymyalgia rheumatica.
    Fernández-Castro M; Andreu JL; Muñoz P; Ornilla E
    Clin Exp Rheumatol; 2004; 22(4):505. PubMed ID: 15301257
    [No Abstract]   [Full Text] [Related]  

  • 45. Unusual case of recurrent falls: myasthenia gravis in an elderly patient.
    Alaama T; Basharat P; Nicolle MW
    Can Fam Physician; 2012 Nov; 58(11):1231-2. PubMed ID: 23152461
    [No Abstract]   [Full Text] [Related]  

  • 46. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.
    Feng X; Huan X; Yan C; Song J; Lu J; Zhou L; Wu H; Qiao K; Lu J; Xi J; Luo S; Zhao C
    Eur Neurol; 2020; 83(2):182-188. PubMed ID: 32526733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ocular myasthenia gravis in a senior population: diagnosis, therapy, and prognosis.
    Allen JA; Scala S; Jones HR
    Muscle Nerve; 2010 Mar; 41(3):379-84. PubMed ID: 19918767
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Benatar M; Kaminski HJ;
    Neurology; 2007 Jun; 68(24):2144-9. PubMed ID: 17460154
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.
    Abuzinadah AR; Jabari D; Jawdat O; Pasnoor M; Glenn M; Herbelin L; McVey AL; Barohn RJ; Dimachkie MM
    J Clin Neuromuscul Dis; 2018 Dec; 20(2):49-59. PubMed ID: 30439750
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial.
    Benatar M; Sanders DB; Wolfe GI; McDermott MP; Tawil R
    Ann N Y Acad Sci; 2012 Dec; 1275():17-22. PubMed ID: 23278573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
    Chirapapaisan N; Tanormrod S; Chuenkongkaew W
    Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ocular Myasthenia Induced by Rivaroxaban in Patient with Deep Vein Thrombosis.
    San Norberto EM; García-Saiz I; Gutiérrez D; Domingos L; Vaquero C
    Ann Vasc Surg; 2018 May; 49():313.e1-313.e3. PubMed ID: 29455019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double seronegative myasthenia gravis with low density lipoprotein-4 (LRP4) antibodies presenting with isolated ocular symptoms.
    Tsivgoulis G; Dervenoulas G; Kokotis P; Zompola C; Tzartos JS; Tzartos SJ; Voumvourakis KI
    J Neurol Sci; 2014 Nov; 346(1-2):328-30. PubMed ID: 25248951
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic yields and clinical features of ocular myasthenia gravis.
    Kim H; Oh SY
    Medicine (Baltimore); 2021 Jun; 100(25):e26457. PubMed ID: 34160444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of steroid treatment in myasthenia gravis: a retrospective study.
    Cosi V; Citterio A; Lombardi M; Piccolo G; Romani A; Erbetta A
    Acta Neurol Scand; 1991 Jul; 84(1):33-9. PubMed ID: 1927259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ocular myasthenia gravis: predictive value of single-fiber electromyography.
    Weinberg DH; Rizzo JF; Hayes MT; Kneeland MD; Kelly JJ
    Muscle Nerve; 1999 Sep; 22(9):1222-7. PubMed ID: 10454717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical features of double seronegative ocular myasthenia gravis.
    Goto T; Kimura A; Masuda A; Mochizuki Y; Gomi F
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; 262(8):2617-2623. PubMed ID: 38416235
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
    Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
    Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Ocular myasthenia].
    Huber A
    Klin Monbl Augenheilkd; 1985 Mar; 186(3):158-60. PubMed ID: 3999598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.